Sugi Predict

Sugi Predict / Compounds / SCHEMBL656156

SCHEMBL656156

SCHEMBL656156

CCOC(=O)c1cc2cc([N+](=O)[O-])ccc2[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.67
▸ ALDH1A1 P00352 3/20 0.67
▸ HPGD P15428 3/20 0.67
▸ RAB9A P51151 3/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ NPC1 O15118 2/20 0.62
▸ LMNA P02545 2/20 0.62
▸ HTT P42858 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ HRH3 Q9Y5N1 1/20 0.62
▸ MMP13 P45452 7/20 0.61
▸ MMP2 P08253 5/20 0.61
▸ MAPT P10636 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ GLA P06280 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ ATM Q13315 1/20 0.58
▸ MMP14 P50281 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5738096 0.90 MMP13 (0.69) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL394554 0.90 ALOX15 (0.64) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL5087401 0.89 MMP13 (0.65) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL6323164 0.85 HRH4 (0.58) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL7681846 0.83 PDE1C (0.52) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL7155166 0.82 HRH4 (0.55) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3943559 0.81 CYP19A1 (0.47) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
Ethyl Acetate SCHEMBL27658176 0.81 ALDH1A1 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL12862878 0.80 HRH4 (0.62) ALDH1A1MAPTMEN1KMT2AHRH4
SCHEMBL30994860 0.80 RAB9A (1.00) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114605303-A Synthesis method of delavirdine and intermediate thereof 武汉工程大学 2022-06-10 — — CN claimed
CN-107739368-B N-substituted-5- ((4-substituted pyrimidine-2-yl) amino) indole derivatives, and preparation method and application thereof 厦门大学 2020-02-14 — — CN claimed
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 — — EP claimed
CN-105037422-B Preparation method of indole phosphonate derivative 苏州大学 2017-05-10 — — CN claimed
US-9447105-B2 Triazine compounds and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-09-20 — — US claimed
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-10 — — US claimed
EP-2948454-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) 2015-12-02 — — EP claimed
CN-105037422-A Preparation method of indole phosphonate derivative UNIV SOOCHOW 2015-11-11 — — CN claimed
CN-104926868-A Method for preparing indole phosphonate derivative ZHANGJIAGANG INST IND TECHNOLOGIES SOOCHOW UNIV 2015-09-23 — — CN claimed
WO-2014115171-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-07-31 — — WO claimed
EP-4747283-A1 TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 — — EP disclosed
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 — — WO disclosed
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same KUKJE PHARMA CO., LTD. (KR) 2025-11-11 — — US disclosed
EP-4568971-A1 ANTAGONISTS OF 5-HYDROXYTRYPTAMINE RECEPTOR SUBTYPE 2B Vanderbilt University (US) 2025-06-18 — — EP disclosed
CN-120129535-A Tissue factor antibody-drug conjugates and uses thereof 埃克塞里艾克西斯公司 2025-06-10 — — CN disclosed
EP-0586254-A1 Furanoindoline derivatives and their use as antitumor agents ELI LILLY AND COMPANY (US) 1994-03-09 — — EP disclosed
EP-0563475-A1 Cell binding agent conjugates of derivatives of CC-1065 IMMUNOGEN INC (US) 1993-10-06 — — EP disclosed
US-5248691-A Antitumor agent ELI LILLY AND COMPANY (US) 1993-09-28 — — US disclosed
EP-0088350-B1 CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1985-02-20 — — EP disclosed
EP-0088350-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1983-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same PTGES, PTGES2, PTGS1 KDM4E 2460/4885ALDH1A1 331/4885HPGD 10/4885
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF TPH2, IDO2, INMT KDM4E 862/4885ALDH1A1 2885/4885HPGD 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.